New Mathematical HIV Prediction Models by EuResist Project

EuResist ProjectA cure for the virus that causes AIDS may still be beyond our grasp, but European researchers have developed a predictive software system for HIV that could help extend the lives of victims of the killer disease.

Despite significant progress in the management of the HIV virus that causes AIDS, today's best treatments do not totally eradicate the virus. The virus' ability to develop resistance to current antiretroviral therapy (ARVT) means the therapy needs to be changed if it is to continue to be effective.

By focusing on the genotype of the virus - information which is inexpensive and easily available - and combining this with clinical information about the patient, researchers behind the EU-funded EuResist project developed new mathematical prediction models.

"In cases where there is a long history of resistance, this is an indicator of death, so it is important to try all the possibilities," says Francesca Incardona, EuResist's coordinator. For non-crucial cases, this may help reduce the cost of the therapy, by choosing the right combination of drugs that work for the longest time, she suggests.

EuResist's key achievement was to combine data from HIV databases in Italy, Sweden and Germany, giving "probably the largest database of its kind in the world", according to Incardona.

Combining the world's largest databases and newly created software has given the project the ability to predict how the HIV virus will react in a certain person given a certain combination of drugs. And this performance is better than the current state-of-the-art predictive systems available to medical researchers, says Incardona, who is based at Italian company Informa.

The achievements of EuResist translate into better medicine, lower treatment-related toxicity and cost savings - giving considerable hope to the 40 million people infected with the virus worldwide. Strength in numbers.

Combining the data from the three national databases was the first and probably most important step, suggests Incardona. It was not only a cyber-merger, but a physical merger, too.

All of the information is now located in what the EU researchers claim as the world's biggest database of AIDS resistance-related information with more than 18,000 patients, 64,000 therapies, and 240,000 viral mode measurements.

With all this data, medical researchers and doctors can now predict what would happen if a patient with a certain type of virus and certain viral load is given a certain combination of ARVT.

Accurate and reliable prediction of future responses to treatment is based on three basic pieces of information: A quantification of the viral load, a definition of the viral genotype, and the viral load after eight weeks of treatment.

The researchers then include other information, such as how the virus is transmitted - sexual or via a blood transfusion - the gender of the person, the sexual preference of the person, whether they are drug abusers and other.

Three different but complementary programmes were developed by the project partners. Each uses the same type of mathematical model to classify a given drug combination as successful or unsuccessful, but is fed with different information. In fact, three approaches are used to extract data from the database to account for different aspects of the disease evolution.

So how well do these engines perform? The researchers evaluated them separately (and in combination) and found that EuResist's model was 76 percent accurate, which was better than the state-of-the-art HIV resistance database at Stanford University, USA.

Compared to the existing systems, which calculate only according to single drugs, the EuResist model can account for combinations of therapies, bringing the results closer to everyday situations.

The EU-funded project is drawing to a close but the partners are determined to create a legacy. Researchers from the three academic partners - Italy's University of Siena, Sweden's Karolinska Institute, and Germany's Max Planck Institute - together with Informa have created the EuResist Network GEIE, a European not-for-profit organisation.

The aim of the network is to maintain the database and make both it and the predictive programs available to medical researchers and doctors all over the world.

At the centre of this network is a web interface, which Incardona says will be free on the web for the global medical community.

And the potential of the project does not stop with the virus that causes AIDS. The breakthroughs from EuResist may also be applicable to every other type of virus that develops resistance to similar prolonged antiretroviral treatments, like hepatitis B and C.

For further information, please visit:
http://www.euresist.org

Related article:

Source: ICT Results

Most Popular Now

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

A Novel AI-Based Method Reveals How Cell…

Researchers from Tel Aviv University have developed an innovative method that can help to understand better how cells behave in changing biological environments, such as those found within a cancerous...